| 沸点 | ~653.7 °C at 760 mmHg |
| 折光率 | 1.63 |
| 溶解性 | DMSO 30 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
| 存贮条件 | 储存温度-20°C |
| 密度 | 1.4000 |
| 应用 | A potent and selective inhibitor of Raf-B protein kinase carrying V600E mutation |
| 产品介绍 | Dabrafenib (达拉菲尼; GSK2118436)是高活性BRAFV600特异性抑制剂，IC50为0.8 nM，比对野生型B-Raf和c-Raf的抑制性高4倍和6倍。 |
| 备注 | Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3. |
| 生化机理 | Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. |
| 别名 | 达拉菲尼;GSK-2118436A; GSK-2118436; GSK2118436A; GSK2118436A; GSK 2118436; GSK 2118436; N-(3-(5-(2-氨基-4-嘧啶基)-2-(叔丁基)-4-噻唑基)-2-氟苯基)-2,6-二氟苯磺酰胺;;GSK-2118436A;GSK-2118436;GSK2118436A;GSK2118436A;GSK 2118436;GSK 2118436;n-(3-(5-(2-amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide |
达拉菲尼
Dabrafenib （订货以英文为准）
编号：D127289
CAS号：1195765-45-7
分子式：C23H20F3N5O2S2
分子量：519.56
| 产品名称 | Dabrafenib |
| 中文名称 | 达拉菲尼 |
| CAS号 | 1195765-45-7 |
| 分子式（M.F.） | C23H20F3N5O2S2 |
| 分子量（M.W.） | 519.56 |
| 储存条件 | -20°C储存 |
技术规格
| Background: | The liver X receptors, LXRA (NR1H3; MIM 602423) and LXRB, form a subfamily of the nuclear receptor superfamily and are key regulators of macrophage function, controlling transcriptional programs involved in lipid homeostasis and inflammation. The inducible LXRA is highly expressed in liver, adrenal gland, intestine, adipose tissue, macrophages, lung, and kidney, whereas LXRB is ubiquitously expressed. Ligand-activated LXRs form obligate heterodimers with retinoid X receptors (RXRs; see MIM 180245) and regulate expression of target genes containing LXR response elements (summary by Korf et al., 2009 [PubMed 19436111]). |
| Applications: | ELISA, IHC |
| Name of antibody: | NR1H2 |
| Immunogen: | Fusion protein of human NR1H2 |
| Full name: | nuclear receptor subfamily 1 group H member 2 |
| Synonyms: | NER; UNR; LXRB; LXR-b; NER-I; RIP15 |
| SwissProt: | P55055 |
| ELISA Recommended dilution: | 5000-10000 |
| IHC positive control: | Human thyroid cancer |
| IHC Recommend dilution: | 150-300 |
搜索质检报告(COA)
搜索MSDS
相关产品
党沛 
